sorafenib has been researched along with Left Ventricular Hypertrophy in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogdanova, A; Daryadel, A; Frossard, N; Gassmann, M; Lehalle, C; Mueller, X; Seifert, B; Tavakoli, R; Zünd, G | 1 |
1 other study(ies) available for sorafenib and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.
Topics: Animals; Becaplermin; Blood Pressure; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Heart Ventricles; Hypertrophy, Left Ventricular; Male; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins c-sis; Rats; Rats, Inbred Lew; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2014 |